FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Sumner Michael John 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)
660 W. GERMANTOWN PIKE, SUITE 110
3. Date of Earliest Transaction (MM/DD/YYYY)
6/30/2022
(Street)
PLYMOUTH MEETING, PA 19462
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Options  $1.73  6/30/2022    A     160000       (1) 6/30/2032  Common Stock  160000.0  $0  160000  D   
Restricted Stock Unit   (2) 6/30/2022    A     105000       (2)  (2) Common Stock  105000.0  $0 (2) 105000  D   

Explanation of Responses:
(1)  The vesting schedule for the 160,000 options is as follows: 40,000 shares vested on June 30, 2022; 40,000 shares will vest on June 30, 2023; 40,000 shares will vest on June 30, 2024; 40,000 shares will vest on June 30, 2025.
(2)  Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares will vest on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Sumner Michael John
660 W. GERMANTOWN PIKE
SUITE 110
PLYMOUTH MEETING, PA 19462


Chief Medical Officer

Signatures
/s/ Michael John Sumner 7/6/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Inovio Pharmaceuticals Charts.
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Inovio Pharmaceuticals Charts.